

NDA 216614  
NADA N-141-549

**DEEMED GRANTED -  
MEDICAL GAS CERTIFICATION REQUEST**

Middlesex Gases Technologies, Inc.  
Attention: Mike Beaulieu, Manager of Quality Control Technical Services  
292 2<sup>nd</sup> Street  
Everett, MA 02149

Dear Mike Beaulieu:

Please refer to your August 13, 2021, request for certification of Carbon Dioxide, USP as a designated medical gas. You have requested to market Carbon Dioxide, USP, for both human and animal use.

A request for certification of a medical gas as a designated medical gas submitted under section 575(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is deemed to be granted unless, within 60 days of the filing of the request, FDA finds that one or more of the bases for denying the request listed at section 575(a)(2) of the FD&C Act applies. FDA has made no such finding in connection with your request, and 60 days have passed since your request was filed. Accordingly, by operation of section 575(a)(2) of the FD&C Act, your request for certification of Carbon Dioxide, USP, as a designated medical gas is deemed to be granted, and you now have in effect an approved new drug application (NDA 216614) and an approved new animal drug application (NADA N-141-549) for this gas effective 10/18/2021.

If any of the information you have submitted in connection with your request changes, such as where the gas is manufactured or changes in applicant information, you will need to submit an updated certifications request to these same NDA/NADA application numbers. please consult section IV.D of the draft guidance document entitled Certification Process for Designated Medical Gases (available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332136.pdf> for additional information. Please cite the NDA/NADA application numbers listed above at the top of the first page of any communications concerning these applications.

We encourage the submission of Designated Medical Gas submissions electronically via the CDER NextGen Portal located here: <https://edm.fda.gov/EDMIDPLogin/welcome>. If you choose to instead submit your application in paper, send the paper submissions, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Pharmaceutical Quality  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Please do not mail any paper copies of submissions submitted via the CDER NextGen Portal.

If you have any questions, please contact Elisa Nickum, Regulatory Business Process Manager, at [elisa.nickum@fda.hhs.gov](mailto:elisa.nickum@fda.hhs.gov) or 301) 796-4226.

Sincerely,

**Charles J.  
Andres -S**

Digitally signed by Charles J.  
Andres -S  
Date: 2021.10.18 14:32:55  
-04'00'

Charles J. Andres, Ph.D.  
Director Division of Business Information Science and Management  
Office of New Animal Drug Evaluation, HFV-180  
Center for Veterinary Medicine  
FDA

**Michael M.  
Folkendt -S**

Digitally signed by Michael M. Folkendt -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People,  
0.9.2342.19200300.100.1.1=1300085536,  
cn=Michael M. Folkendt -S  
Date: 2021.10.18 16:16:36 -04'00'

Michael M. Folkendt  
Associate Director for Regulatory Affairs  
Office of Program and Regulatory Operations  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research  
FDA